- Home
- LPCN vs ANTX Comparison
LPCN vs ANTX Comparison
Compare LPCN & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPCN
- ANTX
- Stock Information
- Founded
- LPCN 1997
- ANTX 2017
- Country
- LPCN United States
- ANTX United States
- Employees
- LPCN N/A
- ANTX N/A
- Industry
- LPCN Biotechnology: Pharmaceutical Preparations
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- LPCN Health Care
- ANTX Health Care
- Exchange
- LPCN Nasdaq
- ANTX Nasdaq
- Market Cap
- LPCN 36.8M
- ANTX 31.9M
- IPO Year
- LPCN N/A
- ANTX 2022
- Fundamental
- Price
- LPCN $4.81
- ANTX $1.43
- Analyst Decision
- LPCN Strong Buy
- ANTX Hold
- Analyst Count
- LPCN 1
- ANTX 5
- Target Price
- LPCN $10.00
- ANTX $3.50
- AVG Volume (30 Days)
- LPCN 28.3K
- ANTX 729.8K
- Earning Date
- LPCN 11-07-2024
- ANTX 11-13-2024
- Dividend Yield
- LPCN N/A
- ANTX N/A
- EPS Growth
- LPCN N/A
- ANTX N/A
- EPS
- LPCN N/A
- ANTX N/A
- Revenue
- LPCN $7,922,926.00
- ANTX N/A
- Revenue This Year
- LPCN N/A
- ANTX N/A
- Revenue Next Year
- LPCN N/A
- ANTX N/A
- P/E Ratio
- LPCN N/A
- ANTX N/A
- Revenue Growth
- LPCN N/A
- ANTX N/A
- 52 Week Low
- LPCN $2.38
- ANTX $0.87
- 52 Week High
- LPCN $11.79
- ANTX $22.22
- Technical
- Relative Strength Index (RSI)
- LPCN 41.11
- ANTX 77.50
- Support Level
- LPCN $4.64
- ANTX $0.98
- Resistance Level
- LPCN $4.98
- ANTX $1.33
- Average True Range (ATR)
- LPCN 0.51
- ANTX 0.06
- MACD
- LPCN -0.12
- ANTX 0.03
- Stochastic Oscillator
- LPCN 5.12
- ANTX 98.59
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.